Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Kidney International

Volumn 83, Issue 1, 2013, Pages 129-137

  Gou, Shen Ju ^a   Yuan, Jun ^a,b   Chen, Min ^a   Yu, Feng ^a   Zhao, Ming Hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

alternative pathway; anti neutrophil cytoplasmic antibody; complement; vasculitis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPERDIN;

ADOLESCENT; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; UPREGULATION;

EID: 84871785269     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.313     Document Type: Article

References (29)

1. Segelmark M, Wieslander J. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA). Nephrol Dial Transplant 1993; 8: 696-702.
2. Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997; 8: 314-322.
3. Xiao H, Schreiber A, Heeringa P et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170: 52-64.
4. Huugen D, van EA, Xiao H et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007; 71: 646-654.
5. Schreiber A, Xiao H, Jennette JC et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20: 289-298.
6. Chen M, Xing GQ, Yu F et al. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant 2009; 24: 1247-1252.
7. Xing GQ, Chen M, Liu G et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29: 282-291.
8. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-678.
9. Watanabe H, Noguchi E, Shio K et al. Usefulness of complement split product, Bb, as a clinical marker for disease activity of lupus nephritis. Fukushima J Med Sci 2006; 52: 103-109.
10. Pavlov IY, De Forest N, Delgado JC. Specificity of EIA immunoassay for complement factor Bb testing. Clin Lab 2011; 57: 225-228.
11. Ganter MT, Brohi K, Cohen MJ et al. Role of the alternative pathway in the early complement activation following major trauma. Shock 2007; 28: 29-34.
12. Alegretti AP, Mucenic T, Merzoni J et al. Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients. Cell Immunol 2010; 265: 127-132.
13. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963.
14. Edelbauer M, Kshirsagar S, Riedl M et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011; 26: 401-410.
15. Manzi S, Rairie JE, Carpenter AB et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996; 39: 1178-1188.
16. Watanabe H, Garnier G, Circolo A et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 2000; 164: 786-794.
17. Sato N, Ohsawa I, Nagamachi S et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus 2011; 20: 1378-1386.
18. Ogden CA, deCathelineau A, Hoffmann PR et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781-795.
19. Gullstrand B, Martensson U, Sturfelt G et al. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 2009; 156: 303-311.
20. Crehan H, Holton P, Wray S et al. Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology 2012; 217: 244-250.
21. Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20: 271-277.
22. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-617.
23. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
24. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
26. Bajema IM, Hagen EC, Hansen BE et al. The renal histopathology in systemic vasculitis: an international survey study of inter-and intra-observer agreement. Nephrol Dial Transplant 1996; 11: 1989-1995.
27. Bajema IM, Hagen EC, Hermans J et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999; 56: 1751-1758.
28. Hauer HA, Bajema IM, van HHC et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61: 80-89.
29. Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 2001; 180: 35-48.